# Purdue Pharma LP clinical trials: 58 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 58 trials with Purdue Pharma LP as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Purdue Pharma LP: 58 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/purdue-pharma-lp

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 58
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 58, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 6, 2024 | NCT06719986 | Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg | Purdue Pharma LP | Phase 1 | Completed | Opioid Overdose | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06719986) |
| April 12, 2023 | NCT05808881 | Clinical Outcomes From Nalmefene | Purdue Pharma LP | Phase 4 | Withdrawn | Opioid Overdose | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05808881) |
| August 3, 2021 | NCT04987762 | Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children | Purdue Pharma LP | Phase 4 | Terminated | Attention Deficit/Hyperactivity Disorder | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04987762) |
| August 11, 2020 | NCT04507204 | Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) | Purdue Pharma LP | Phase 4 | Terminated | Attention-Deficit/Hyperactivity Disorder | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04507204) |
| October 3, 2017 | NCT03299556 | Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System | Purdue Pharma LP | Observational | Completed | Chronic Pain | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03299556) |
| January 23, 2017 | NCT03028870 | A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee | Purdue Pharma LP | Phase 2 | Completed | Osteo Arthritis Knee | 291 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03028870) |
| July 28, 2016 | NCT02847702 | A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee | Purdue Pharma LP | Phase 2 | Terminated | Osteoarthritis Pain of the Knee | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02847702) |
| March 1, 2016 | NCT02695745 | Experimental Biomarker Study for Pain Thresholds | Purdue Pharma LP | Phase 1 | Completed | Pain | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02695745) |
| September 4, 2015 | NCT02542098 | Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children | Purdue Pharma LP | Phase 2 | Withdrawn | Pain | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02542098) |
| September 17, 2014 | NCT02243241 | The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects | Purdue Pharma LP | Phase 1 | Completed | Healthy | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02243241) |
| December 3, 2013 | NCT01999114 | The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone... | Purdue Pharma LP | Phase 1 | Completed | ECG Effects | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01999114) |
| July 16, 2013 | NCT01900795 | An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction | Purdue Pharma LP | Phase 2 | Terminated | Postsurgical Pain Due to Third Molar Extraction | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01900795) |
| September 20, 2012 | NCT01688947 | Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) | Purdue Pharma LP | Phase 2 | Completed | Postherpetic Neuralgia, Pain | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01688947) |
| September 20, 2012 | NCT01688934 | Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee | Purdue Pharma LP | Phase 2 | Completed | Osteoarthritis, Knee, Pain | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01688934) |
| October 17, 2011 | NCT01452529 | Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain | Purdue Pharma LP | Phase 3 | Completed | Chronic Low Back Pain | 905 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01452529) |
| September 1, 2011 | NCT01427283 | A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation... | Purdue Pharma LP | Phase 3 | Completed | Low Back Pain | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01427283) |
| September 1, 2011 | NCT01427270 | Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain | Purdue Pharma LP | Phase 3 | Completed | Low Back Pain | 455 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01427270) |
| July 22, 2011 | NCT01400139 | Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain.... | Purdue Pharma LP | Phase 3 | Completed | Chronic Nonmalignant and Nonneuropathic Pain | 922 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01400139) |
| June 9, 2011 | NCT01369615 | Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001 | Purdue Pharma LP | Phase 3 | Completed | Pain | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01369615) |
| May 23, 2011 | NCT01358526 | Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate... | Purdue Pharma LP | Phase 3 | Completed | Low Back Pain | 1,095 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01358526) |
| March 29, 2011 | NCT01324570 | Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children | Purdue Pharma LP | Phase 3 | Completed | Pain | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01324570) |
| March 29, 2011 | NCT01324544 | Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute... | Purdue Pharma LP | Phase 3 | Withdrawn | Other Acute Postoperative Pain, Prolonged Endotracheal Intubation | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01324544) |
| December 13, 2010 | NCT01259115 | Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and... | Purdue Pharma LP | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01259115) |
| December 13, 2010 | NCT01259102 | Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable... | Purdue Pharma LP | Phase 1 | Completed | Healthy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01259102) |
| September 1, 2010 | NCT01192295 | Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant... | Purdue Pharma LP | Phase 3 | Completed | Pain | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01192295) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 2 | 8 |
| Phase 3 | 29 |
| Phase 4 | 4 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 43 |
| Terminated | 12 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Chronic Pain | 12 |
| Osteoarthritis | 12 |
| Pain | 11 |
| Low Back Pain | 7 |
| Pain, Postoperative | 4 |
| Osteoarthritis, Knee | 4 |
| Agnosia | 2 |
| Attention Deficit Disorder with Hyperactivity | 2 |
| Back Pain | 2 |
| Opiate Overdose | 2 |
| Constipation | 2 |
| Acute Pain | 1 |
| Neuralgia, Postherpetic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Engineering firms in the United States](https://specstream.ai/data/businesses/engineering-firms/united-states)
- [Spring suppliers in the United States](https://specstream.ai/data/businesses/spring-suppliers/united-states)
- [Fireplace services in the United States](https://specstream.ai/data/businesses/fireplace-services/united-states)
- [Tiki bars in the United States](https://specstream.ai/data/businesses/tiki-bars/united-states)
- [Glass manufacturers in the United States](https://specstream.ai/data/businesses/glass-manufacturers/united-states)
- [Vehicle shipping companies in the United States](https://specstream.ai/data/businesses/vehicle-shipping-companies/united-states)
